The health landscape faces challenges due to various policies, including Trump's stance on transgender care and CDC research, ...

Sanofi (NASDAQ:SNY – Free Report) by 25.6% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 314,180 shares of the company’s stock ...

The recent FDA approvals of two treatments for molluscum contagiosum may represent a shift in how clinicians view this disease, according to a speaker at Masters of Pediatric Dermatology.In an ...

Just days after taking back some of the stake held by L’Oréal, Sanofi has agreed to repurchase its own shares worth €2bn ($2.08bn) from other stakeholders. The French drugmaker said it had entered a ...

As previously reported, L’Oréal sales in the three months ended Dec. 31 reached 11.08 billion euros, up 4.5 percent in ...

As the U.S. continues to wait for newer sunscreen ingredients, patients should use tinted sunscreens to protect against visible light that causes photodamage, melasma and hyperpigmentation, according ...

Although a waiver was placed on HIV/AIDS programmes in last month's U.S. foreign aid funding freeze, many concerns remained about the future of treatment programmes, the deputy executive director of ...

"Medidata is at the forefront of a critical shift in the life sciences sector," said Anthony Costello, CEO, Medidata. "By harnessing AI-powered solutions and partnering with visionaries, we aren't ...

Sanofi, AstraZeneca and two leading trade groups want clarity around an appellate decision that called for Teva to delist ...

Early results from a trial testing a 2009 H1N1 influenza vaccine in children look promising, according to the trial sponsor, the National Institute of Allergy and Infectious Diseases (NIAID), part ...

The first recipient of a gene-edited pig kidney died from cardiac causes 52 days after xenotransplantation. The world's first ...

Kite, a Gilead Sciences company, will share four posters that add to the growing body of evidence to support the clinical use of its chimeric antigen receptor (CAR) T-cell therapy portfolio, at the ...